Drugs / PORGAVIXIMAB
PORGAVIXIMAB
also known as
c2G4 · Porgaviximab component of zmap c2g4 · Porgaviximab component of zmapp c2g4 · Zmapp
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02389192 | Mar 2015 → Dec 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PORGAVIXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989996 ↗ |
| Known as | c2G4 | “ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes” NCT02389192 ↗ |
| Known as | Porgaviximab component of zmap c2g4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989996 ↗ |
| Known as | Porgaviximab component of zmapp c2g4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989996 ↗ |
| Known as | Zmapp | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989996 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3989996 ↗ |